Multiple Sclerosis (MS) market Dynamics Exploring Growth Opportunities and Technological Advances Up to 2030

1
Multiple Sclerosis (MS) Market Trends, Size,
Share, Demands, Overview, Growth, Revenue and
Forecast to 2030
sales_at_delvens.com www.delvens.com
2

Multiple Sclerosis (MS) Market, By Type
(Clinically isolated syndrome (CIS),
Relapse-remitting MS (RRMS), Primary progressive
MS (PPMS), Secondary progressive MS (SPMS)),
Treatment (Medications, Stem Cell Therapy,
Physical Therapy, Plasma Exchange, Others), Drug
Class (Immunomodulators, Immunosuppressants,
Interferons, Others), Diagnosis (Magnetic
Resonance Imaging (MRI), Simple Electrical
Stimulation Tests, Lumbar Puncture, Others),
Route of Administration (Oral, Parenteral,
Others), End-Users (Hospitals, Specialty Clinics,
Homecare, Others), Distribution Channel (Hospital
Pharmacy, Retail Pharmacy, Online Pharmacy,
Others) and region (North America, Europe,
Asia-Pacific, Middle East and Africa and South
America).
Request For Free Sample Report
https//www.delvens.com/get-free-sample/multiple-s
clerosis-ms-market
sales_at_delvens.com
www.delvens.com
3
Market Overview
Multiple sclerosis is a chronic inflammatory
disease that causes demyelination, cutting of
axons and degeneration of neurons in the brain
and spinal cord. The body's immune system targets
neurons in the central nervous system and damages
the myelin sheath. It is a potentially
debilitating disease that causes disturbances in
the body's communication and coordination.
Symptoms of multiple sclerosis vary greatly
depending on the extent of the damage and the
number of neurons affected. Some of the observed
symptoms include fatigue, numbness, spasticity,
bladder dysfunction, cognitive changes, emotional
changes and depression. A person with severe MS
has speech and movement problems. Multiple
sclerosis can be divided into four types RRMS,
SPMS, PPMS and PRMS. The growth is due to the
fact that major market players have invested in
RD to develop innovative medicines. For example,
in December 2020, Adamas Pharmaceuticals Inc.
announced Results of a phase 3 clinical trial of
amantadine ADS-5102 for the treatment of MS
patients. Product launches, increasing government
initiatives to improve access to treatment and
care, and increasing prevalence of multiple
sclerosis are expected to drive global market
expansion. Purchase this Report
https//www.delvens.com/checkout/multiple-sclerosi
s-ms-market
sales_at_delvens.com
www.delvens.com
4
Key Findings
The Multiple Sclerosis (MS) Market is segmented
into various segments such type, drug class,
treatment, diagnosis, route of administration,
end-users, distribution channel and region The
Drug Class segment is further fragmented into
Immunomodulators, Immunosuppressants, Interferons
and others. The immunomodulators segment is
expected to account for a larger market size
during the forecast period. Higher prescription
rates, brand loyalty, and the presence of a wide
range of drug alternatives are some key drivers
attributing to its largest share. The
Distribution Channel segment is further
bifurcated into Hospital Pharmacy, Retail
Pharmacy, Online Pharmacy and Others. The
Hospital Pharmacy is the largest market during
the forecast period. owing to favorable health
reimbursement and increased government efforts to
strengthen the government hospital pharmacies.
Moreover, the online pharmacy segment is poised
to experience lucrative growth due to the
increasing number of online portals
distributing prescription drugs across the globe.
Moreover, due to the outbreak of COVID-19,
lockdown restrictions were imposed globally to
control the spread of the virus. This increased
the need for home delivery of medicines, thereby
spurring segmental growth.
sales_at_delvens.com
www.delvens.com
5
Key Findings
The market is also divided into various regions
such as North America, Europe, Asia-Pacific,
South America, and Middle East and Africa. North
America is estimated to account for the largest
market share during the forecast period. Inquire
Before Buying https//www.delvens.com/Inquire-bef
ore-buying/multiple-sclerosis-ms-market
sales_at_delvens.com
www.delvens.com
6
Competitive Landscape

• Genentech, Inc.
• GlaxoSmithKline plc
• Johnson Johnson
• Merck Co., Inc.
• Mylan N.V.
• Novartis AG
• Opexa Therapeutics, Inc.
• Pfizer Inc.
• Sanofi S. A.
• Teva Pharmaceuticals

• Abbott
• AbbVie Inc.
• Acorda Therapeutics Inc.
• Actelion Pharmaceuticals Ltd
• Allergan
• AstraZeneca
• Bayer AG
• Biogen Inc.
• Bristol-Myers Squibb Company
• Cipla Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.

sales_at_delvens.com
www.delvens.com
7
Recent Developments
In June 2022, Sandoz expands its portfolio with
the launch of the generic drug Dimethyl fumarate
HEXAL, which is approved for the treatment of
adults with relapsing-remitting multiple
sclerosis (RRMS) in Germany.  In February
2022, Teva Pharmaceuticals Europe BV confirmed
that the SmPC for COPAXONE (Glatiramer Acetate
(GA) injection) 20mg/mL and 40mg/mL, indicated
for the treatment of relapsing forms of multiple
sclerosis (RMS) in Europe, has been updated.
sales_at_delvens.com
www.delvens.com
8
Contact Information
About Us Delvens is a strategic advisory and
consulting company headquartered in New Delhi,
India. The company holds expertise in providing
syndicated research reports, customized research
reports and consulting services. Delvens
qualitative and quantitative data is highly
utilized by each level from niche to major
markets, serving more than 1K prominent companies
by assuring to provide the information on
country, regional and global business
environment. We have a database for more than 45
industries in more than 115 major countries
globally. Contact Us 44-20-3290-6466 1
214-377-1144 sales_at_delvens.com
sales_at_delvens.com
www.delvens.com